We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Human Genome Sciences Completes Transaction Establishing CoGenesys as an Independent Company
News

Human Genome Sciences Completes Transaction Establishing CoGenesys as an Independent Company

Human Genome Sciences Completes Transaction Establishing CoGenesys as an Independent Company
News

Human Genome Sciences Completes Transaction Establishing CoGenesys as an Independent Company

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Human Genome Sciences Completes Transaction Establishing CoGenesys as an Independent Company "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Human Genome Sciences, Inc. has announced that it has completed the transaction establishing its CoGenesys division as an independent company that will focus on the early development of selected gene-based product opportunities and the monetization of certain HGS intellectual property and technology assets.

In a separate press release, CoGenesys announced the completion of a $55 million Series A financing.

"Through this transaction, HGS will realize value from certain intellectual property assets and early-stage product opportunities that we do not plan to develop internally," said H. Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences.

"HGS will benefit in future years from its right to share in CoGenesys revenues and from its equity interest."

"HGS will maintain its focus on progress toward the commercialization of our lead products, Albuferon for hepatitis C and LymphoStat-B for lupus, both of which are expected to enter Phase 3 clinical trials before the end of 2006."

Advertisement